Comparing Vycor Medical (OTCMKTS:VYCO) and CVRx (NASDAQ:CVRX)

CVRx (NASDAQ:CVRX) and Vycor Medical (OTCMKTS:VYCO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for CVRx and Vycor Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	0	2	4	0	2.67
Vycor Medical	0	0	0	0	N/A

CVRx currently has a consensus target price of $13.60, indicating a potential upside of 70.64%. Given CVRx’s higher possible upside, equities research analysts plainly believe CVRx is more favorable than Vycor Medical.

Institutional & Insider Ownership

75.3% of CVRx shares are held by institutional investors. 18.9% of CVRx shares are held by insiders. Comparatively, 7.0% of Vycor Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares CVRx and Vycor Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CVRx	-122.52%	-72.51%	-49.78%
Vycor Medical	-7.49%	N/A	-10.32%

Risk and Volatility

CVRx has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Vycor Medical has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.

Valuation & Earnings

This table compares CVRx and Vycor Medical’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$44.39 million	3.88	-$41.20 million	($2.47)	-3.23
Vycor Medical	$1.46 million	2.01	-$70,000.00	N/A	N/A

Vycor Medical has lower revenue, but higher earnings than CVRx.

Summary

CVRx beats Vycor Medical on 7 of the 11 factors compared between the two stocks.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

About Vycor Medical

Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. It operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation targeted at people who have impaired vision as a result of stroke or other brain injury. It has a license agreement which grants for the license to provide NovaVision's products and therapies to patients and professionals in Germany, Austria and Switzerland. It primarily serves hospitals and medical professionals. Vycor Medical, Inc. was founded in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. is a subsidiary of Fountainhead Capital Management Limited.